10 CFOs in Biotechnology
Chief financial officers of biotechnology companies such as Editas Medicine, Tessera Therapeutics, Allogene Therapeutics and PacBio make up this group, and their paths differ: five held a CFO title at another company first, four held other titles at their current company before the CFO one, and one moved over from healthcare investment banking. That spread helps a biotech planning runway or a financing, or deciding what kind of CFO to hire.
Professionals to explore
Amy Parison
LinkedInExperience: Chief Financial Officer · Editas Medicine
$1,885 per 30-minute call
Amy Parison has been Chief Financial Officer at Editas Medicine, a gene editing company focused on developing CRISPR medicines, since March 2025, after holding Senior Vice President, Finance (2025) and VP of Finance and Corporate Controller (2022-2025) titles there. Amy was also Senior Director, Corporate Controller at Rubius Therapeutics (2021-2022). The controller path makes Amy a fit for questions on finance operations at a gene editing company.
Is this you? Claim your profile and get paid for calls.
Anne Doering
LinkedInExperience: Chief Financial Officer · Vivoryon Therapeutics N.V.
$1,346 per 30-minute call
Anne Doering, Chief Financial Officer at Vivoryon Therapeutics N.V., a precision medicine company, since March 2024, held the Chief Strategy & Investor Relations Officer (2023-2024) and Head of Investor Relations (2023) titles there first. Anne was Director, Investor Relations at BioNTech SE (2022) and Director, Group Strategy at Merck KGaA (2020-2021), making investor communication Anne's clearest angle.
Is this you? Claim your profile and get paid for calls.
Ellen Snow
LinkedInExperience: Former Chief Financial Officer · Mercy BioAnalytics, Inc.
$1,078 per 30-minute call
Ellen Snow joined Mercy BioAnalytics, Inc., which works on extracellular vesicles for early-stage cancer, as Chief Financial Officer in December 2025, after working as Interim CFO, self-employed (2024-2025). Ellen was SVP, CFO and Treasurer at Akebia Therapeutics (2023-2024) and sits on the Board of Advisors at Merrimack College. A fit for questions on hiring an interim CFO versus a permanent one.
Is this you? Claim your profile and get paid for calls.
Geoffrey Parker
LinkedInExperience: Executive Vice President and Chief Financial Officer · Allogene Therapeutics
$1,885 per 30-minute call
Geoffrey Parker is Executive Vice President and Chief Financial Officer at Allogene Therapeutics (since October 2023) and was Chief Operating Officer, Chief Financial Officer and Executive Vice President at Tricida, Inc. (2017-2023). Geoffrey has been a Board Member at Perrigo Company plc since 2016 and was a Board Member at ChemoCentryx (2009-2022), so can speak to the CFO seat from the board side too.
Is this you? Claim your profile and get paid for calls.
Jim Gibson
LinkedInExperience: Chief Financial Officer · PacBio
$1,750 per 30-minute call
PacBio, which provides long-read sequencing for genomes, transcriptomes and epigenomes, has had Jim Gibson as Chief Financial Officer since March 2025. Jim was also Chief Financial Officer at Sequoia (2023-2025), Willow Innovations, Inc. (2021-2022) and BioElectron Technology Corporation (2017-2019), acquired by PTC Therapeutics in Oct 2019, plus VP of Finance Transformation at GoDaddy (2019-2021). Suited to questions on finance transformation and on moving between CFO roles.
Is this you? Claim your profile and get paid for calls.
Kathleen Borthwick
LinkedInExperience: Chief Financial Officer · Passage Bio
$1,346 per 30-minute call
At Passage Bio, a genetic medicines company focused on CNS disorders, Kathleen Borthwick has been Chief Financial Officer since March 2024 after serving as SVP of Finance, Interim Chief Financial Officer (2021-2024). Kathleen's Johnson & Johnson roles include Group Finance Lead, Medical Devices (2020-2021) and Sr. Director Janssen EMEA Mid-Sized Markets (2018-2020). Interim-to-permanent CFO questions fit Kathleen well.
Is this you? Claim your profile and get paid for calls.
Kathy Bergsteinsson
LinkedInExperience: Chief Financial Officer · Tessera Therapeutics
$1,615 per 30-minute call
Kathy Bergsteinsson became Chief Financial Officer at Tessera Therapeutics, an early-stage life sciences company pioneering Gene Writing, in October 2025, and was Chief Financial Officer at Affini-T Therapeutics (2023-2025). At Morgan Stanley, Kathy was Managing Director - Equity Capital Markets (2011-2023) and Vice President - Mergers and Acquisitions Department (2005-2010), useful for questions on equity raises and deal options.
Is this you? Claim your profile and get paid for calls.
Michael Mason
LinkedInExperience: Chief Financial Officer · Pioneering Medicines
$1,211 per 30-minute call
Michael Mason, Chief Financial Officer at Pioneering Medicines since November 2024, was Chief Financial Officer at Karyopharm Therapeutics Inc. (2019-2024), Vice President of Finance & Treasurer at Alnylam Pharmaceuticals (2005-2019) and Controller at Praecis Pharmaceuticals (2000-2005). Two CFO roles and a long stint as treasurer suit questions on treasury and on being CFO a second time.
Is this you? Claim your profile and get paid for calls.
Robert Renninger
LinkedInExperience: Chief Financial Officer · LeonaBio
$1,211 per 30-minute call
Robert Renninger's titles at LeonaBio are Chief Financial Officer since December 2025, SVP Finance and Accounting (2025), VP Finance and Accounting (2022-2025), Senior Director of Finance (2020-2022) and Director of Finance (2020). LeonaBio has 30-40 employees, so Robert is a good contact for running finance and accounting at a biotech of that size.
Is this you? Claim your profile and get paid for calls.
Vishaal Turakhia
LinkedInExperience: Chief Financial Officer · Endeavor BioMedicines
$1,346 per 30-minute call
Endeavor BioMedicines, a clinical-stage biotechnology company, has had Vishaal Turakhia as Chief Financial Officer since March 2024. Directly before, Vishaal was Managing Director Healthcare Investment Banking at Piper Sandler (2019-2024), with Vice President Healthcare Investment Banking roles at Bank of America Merrill Lynch (2018-2019) and RBC Capital Markets (2012-2018) and Analyst Biotech Equity Research at Goldman Sachs (2010-2012). Strong on financing strategy.
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
For a raise or capital markets question, Vishaal Turakhia and Kathy Bergsteinsson bring investment banking and equity capital markets years. Michael Mason, Jim Gibson, Geoffrey Parker and Ellen Snow have each been CFO at more than one company and suit questions on a second CFO job, while Amy Parison, Kathleen Borthwick, Robert Renninger and Anne Doering are the calls for stepping into the CFO title at the same biotech.
Questions to take into the conversation
- 01How many months of runway do you plan to keep, and which clinical or research readouts set the timing of your next raise?
- 02When several programs compete for cash, how do you and the R&D leads decide which one gets cut first?
- 03What did you change in the finance team when the company started reporting to public-market investors?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.